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 3 
ABSTRACT 
Context 
The frequency of adrenal incidentalomas and their association with comorbid conditions have been 
assessed mostly in retrospective studies that may be prone to ascertainment bias. 
 
Objective 
To evaluate the frequency of adrenal incidentalomas and their associated comorbid conditions. 
 
Design 
Prospective cohort study. 
 
Setting 
Radiology Department at a public hospital. 
 
Partecipants 
Unselected outpatients who underwent an abdominal CT from January 2017 to June 2018. Patients 
with known or suspected adrenal disease or malignancy were excluded. 
 
Exposure 
All abdominal CT scans were evaluated by an experienced radiologist. Hormonal work-up including a 
1-mg dexamethasone suppression test was done in patients bearing adrenal incidentalomas. 
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Main outcome and Measure 
Frequency of adrenal incidentalomas in abdominal CT of unselected patients; frequency of comorbid 
conditions, and hormonal work-up in patients bearing adrenal incidentalomas. 
 
Results 
We recruited 601 patients and in 7.3% of them an adrenal tumor was found serendipitously. The 
patients bearing an adrenal incidentaloma had higher BMI (p=0.009) and waist (p=0.007) and were 
more frequently diabetic (p=0.0038). At multivariate regression analysis, diabetes was significantly 
associated with the presence of adrenal incidentalomas (p=0.003). Autonomous cortisol secretion was 
observed in 50% of patients who did not suppress cortisol <50 nmol/L after 1 mg dexamethasone.  
 
Conclusions 
The frequency of adrenal incidentalomas is higher than previously reported. Moreover, adrenal 
incidentalomas are tied to increased risk of type 2 diabetes. This finding is free from ascertainment 
bias because patients with adrenal incidentalomas were drawn from a prospective cohort with the 
same risk of diabetes than the background population. 
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INTRODUCTION 
 
Adrenal tumors are among the most common neoplasms in humans, and the widespread use of high-
resolution cross-sectional imaging in medical practice has increased the frequency of their detection, 
which in most cases occurs serendipitously as adrenal incidentalomas. These tumors are unexpectedly 
found in patients who undergo abdominal scanning for reasons unrelated to any previously suspected 
adrenal disease.  
The frequency of adrenal incidentalomas in CT series assessed in the 1980s and ‘90s ranged from 
0.35 to 1.9% (1-6). In 2006, we reported a frequency of 4.4% in a sample of 520 subjects at risk of 
lung cancer who volunteered for CT screening (7), and more recent studies have confirmed a 
frequency of about 5% (8). This greater frequency of detection is most likely due to the improved 
resolution of modern imaging. 
Most adrenal incidentalomas are benign cortical adenomas that may have secretory activity, although 
patients do not present the classic stigmata of adrenal steroid excess. In 20-30% of adrenal 
incidentalomas, an autonomous cortisol secretion is found that may have clinical consequences (9-
12). To standardize and simplify heterogeneous clinical practice, the European Society of 
Endocrinology and the European Network for the Study of Adrenal Tumors (ESE/ENSAT) guidelines 
recommended a 1 mg overnight dexamethasone suppression test (DST) to exclude cortisol excess 
(10). Cortisol levels following DST < 50 nmol/L (1.8 µg/dL) exclude autonomous cortisol secretion, 
while levels > 138 nmol/L (5.0 µg/dL) should be considered as evidence of autonomous cortisol 
secretion, and levels between the two cutoff points as evidence of possible autonomous cortisol 
secretion (10). 
Autonomous cortisol secretion has been defined as subclinical Cushing’s syndrome or subclinical 
hypercortisolism, and represents the lower end of the Cushing’s syndrome spectrum. An increasing 
body of evidence suggests that is associated with metabolic and cardiovascular diseases that may 
eventually result in excess mortality (13-19).  
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It is biologically plausible that chronic exposure to low-grade cortisol excess resulting from 
autonomous adrenal secretion has clinical consequences, but previous studies are mostly retrospective 
and cannot definitively establish a cause and effect relationship. An inherent bias of these studies is 
that diseased individuals are more likely to undergo imaging examinations than healthy ones, and 
therefore the association between adrenal incidentalomas and diseases such as diabetes, hypertension, 
and metabolic syndrome may to some extent be explained by an ascertainment bias (20). 
Thus, we were prompted to conduct a prospective assessment of patients undergoing abdominal CT 
examinations at a single radiologic unit, with the following aims: i) to evaluate the frequency of 
adrenal incidentalomas in an unselected population consecutively recruited; ii) to evaluate whether 
patients bearing adrenal incidentalomas present more comorbid conditions and increased 
cardiovascular risk than patients without adrenal tumors; and iii) to evaluate the presence of 
autonomous cortisol secretion, as defined by the ESE/ENSAT guidelines (10), and its eventual 
association with comorbid conditions.  
 
SUBJECTS AND METHODS 
We conducted a prospective study at the Radiology Department of the S. Croce e Carle Hospital in 
Cuneo, Italy, between January 2017 and June 2018, on a consecutive series of outpatients who were 
required to undergo abdominal CT examinations as part of their management. One endocrinologist 
(EC) attended the Radiology Department one day per week to recruit potentially eligible participants, 
explaining the purpose of the study and interviewing patients. Those with any history of adrenal 
disease, malignancy, major psychiatric disorder, or who were on previous or current steroid treatment, 
or any drug (including estrogens) known to interfere with steroid hormone secretion and metabolism, 
were considered as non-eligible. We also excluded patients who underwent CT for oncological 
screening or suspected cancer. All of the study procedures were approved by our institutional research 
and ethics review board and all the patients included in the study provided written informed consent.  
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The height (cm) and weight (kg) of the patients, in light clothing and without shoes, were measured 
using the same device. Body mass index [BMI (kg/m2)] was then calculated and a BMI of >30 
kg/m2 was considered as evidence of obesity. Participants were considered to have abdominal obesity 
if their waists were >102 cm for males or >85 cm for females. Blood pressure (mm Hg) was recorded 
twice using a mercury manometer in a sitting position after the patient rested for more than 15 
minutes, and the average value was calculated. Hypertension was defined as blood pressure >140/90 
mm Hg, or current use of antihypertensive medications. Diabetes mellitus was defined when the 
patient reported fasting glycemia  7 mmol/L, glycemia at 2 h during the oral glucose tolerance test  
11.1 mmol/L, glycated hemoglobin level (HbA1c) ≥6.5%, a previous diagnosis of diabetes, or current 
use of anti-diabetic medications. Dyslipidemia was defined by the current use of cholesterol-lowering 
medications. Any history of cerebrovascular or cardiovascular disease (TIA, stroke, angina pectoris, 
myocardial infarction, or revascularization procedures) was carefully established. Current smoking 
was defined as smoking at least 1 cigarette per day in the past 12 months. We classified women as 
menopausal if their final menstrual period had occurred more than 12 months before. 
All abdominal CT scans were evaluated by an experienced radiologist (MG), who reported the 
presence and number of adrenal tumors and their characteristics [largest size, margins, mass texture 
and attenuation index, which are described as Hounsfield Units (HU)]. The minimal size of adrenal 
lesions to be considered as incidentalomas was ≥10 mm. In case of multiple lesions, the 
characteristics of the largest lesion were used for analysis. CT examinations were performed with a 
Brilliance 64 scan (Philips, Eindhoven, The Netherlands). The technical parameters of CT acquisition 
were adjusted according to the clinical request for the CT scan and to the patient body size. The 
section thickness was 2.5 mm. A helicoidal scan was carried out with 120 kV, 300 mAs, a rotation 
time of 0.42 s, and a pitch of 1.375.  In the event of finding an adrenal mass, a multiplanar 
reconstruction of the whole tumoral area in the sagittal, coronal, and oblique planes was done, with a 
thickness and reconstruction interval of 1 mm, instead of 2.5 mm used in the initial CT evaluation. 
Radiologists reported the maximal density observed in the region of interest. 
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The patients bearing adrenal incidentalomas underwent further work-up, including routine 
biochemical assessment, plasma fractionated metanephrines, ACTH, DHEA-S, and a 1 mg overnight 
dexamethasone suppression test (DST). Plasma Renin Activity and aldosterone were evaluated in 
hypertensive patients. Blood samples were obtained in the morning after overnight fasting. Hormonal 
determinations were conducted in a single lab with routinely available reagents. In particular, serum 
cortisol concentrations were measured using a chemiluminescence immunoassay (CLIA, Siemens), 
with an inter- and intra-assay variation coefficient of 3.7-4.2% and 4.4-6.0%, respectively. DHEAS 
concentrations were measured using a chemiluminescence immunoassay (CLIA, Siemens), with an 
inter- and intra-assay variation coefficient of 4.0-5.6% and 1.6-2.5%, respectively. ACTH 
concentrations were measured using a chemiluminescence immunoassay (CLIA, Diasorin), with an 
inter- and intra-assay variation coefficient of 2.6-5.5% and 2.7-4.3%, respectively. 
Statistical analysis 
Variables were preliminarily tested for normal distribution with the Shapiro-Wilks W test and data 
were expressed as mean ± SD, or median and interquartile range (IQR), as appropriate. Continuous 
variables were compared by the Student’s t-test assuming equal or non-equal variance with the 
Leneve test. Categorical variables were compared by the Chi-square test or Fisher’s exact tests. Two 
separate sets of linear regressions were conducted, and the presence of an adrenal incidentaloma was 
set as the dependent variable. The first set was univariate, and the second included all the variables 
whose β-coefficient was significant in the univariate analysis. In the case of multiple independent 
variables, a multicollinearity test was performed. Variables were rejected from the analysis if there 
was a variance inflation factor greater than two. All statistical analyses were performed using SPSS 
(IBM SPSS Statistics, Version 21). The level of statistical significance was set at p <0.05.  
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RESULTS 
A total of 601 patients were recruited (331 males and 270 females), aged 63.5 ± 14.4 years. They 
underwent CT imaging for the following reasons: urological evaluation (25.4%); varying abdominal 
symptoms (25.1%); virtual colonoscopy (18%); alteration in liver function tests (4.3%); alteration in 
pancreatic enzymes (2.8%); abdominal pain (18%); angiographic studies (16%); hematochezia 
(6.5%); and other reasons (9%).  
The demographic, clinical, and biochemical features of the whole series are summarized in Table 1. 
The demographic characteristics of our cohort are comparable to those of 1332 non-oncologic patients 
undergoing CT examinations at the same radiology department over a 12-month period (male, 62.2%; 
age, 67.9 ± 13.2 years). In terms of clinical characteristics, 55.4% of our patients had hypertension, 
15.5% had diabetes, 17.3% dyslipidemia and 17% a history of previous CV events. The frequency of 
diabetes in the study cohort was comparable to that of the general population of the region, which is 
Piedmont (21,22). 
An adrenal tumor was found serendipitously in 44 patients (7.3%). These were 32 males and 12 
females aged 65.6 ± 10.3 years. The mass size ranged between 10-50 mm (median 21 mm) and the 
tumors were bilateral in 29.5% of patients. In a single case that showed indeterminate features, which 
was 4 cm in size with a density of 30 HU, plasma metanephrine levels were greater than 2 times the 
upper limit of normality, and histology confirmed a diagnosis of pheochromocytoma. The radiologic 
re-assessment using a dedicated protocol of the 43 adrenal adenomas led to detection of 11 tumors 
(25.6%) with a density ranging from 11 HU to 24 HU (Figure 1). In 9 of these patients, a second CT 
was done after 3 to 12 months, and radiologic characteristics of the tumors remained unchanged. 
Thirty-two tumors had the radiological features of benign cortical adenoma (density ≤10 HU). 
A comparison between patients with adrenal incidentalomas and without is given in Table 2. In 
summary, the patients bearing an adrenal incidentaloma were more frequently males, had higher 
BMIs (p = 0.009) and larger waists (p = 0.007), and were more frequently diabetic (p = 0.0038) 
(Table 2). The overall distribution of patients with adrenal incidentalomas by age decades was not 
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fully linear with that of diabetic patients with adrenal incidentalomas (Figure 2), and age of patients 
bearing adrenal incidentalomas with or without diabetes did not differ significantly (69.9 ± 7.1 years 
vs. 63.6 ± 11.0 years; p=NS). In the multivariate regression analysis, diabetes was significantly 
associated with the presence of adrenal incidentalomas (p = 0.003) (Table 3). A 1-mg DST was 
conducted on 40 of the patients, and 20 (50%) did not suppress cortisol < 50 nmol/L, while 4 had 
post-DST cortisol > 138 nmol/L. A comparison between patients stratified by post-DST cortisol < 50 
nmol/L and ≥ 50 nmol/L is provided in Table 4. In summary, no significant difference was found in 
the demographic and clinical characteristics between the two groups, while the size of the dominant 
nodule was significantly larger in patients with post DST cortisol ≥ 50 nmol/L (p = 0.012). The 
difference in mass size was not significantly different when considering the sum of sizes in the event 
of multiple nodules (31.6 ± 16.0 mm vs. 26.2 ± 14.4 mm; p=NS). DHEAS and ACTH concentrations 
were lower in patients with post DST cortisol ≥ 50 nmol/L; however, levels of statistical significance 
were not attained.  
DISCUSSION 
The present study demonstrates that the frequency of adrenal incidentalomas in a prospective series of 
patients is 7.3%, which is higher than previously reported (Table 5)(1-8,23-25). It is important to note 
that we assessed outpatients without any history of adrenal diseases or malignancy, so we may 
conclude that this series is unselected, as far as can be assumed for patients under diagnostic 
evaluation. 
The frequency of adrenal incidentalomas identified in published studies is highly variable, as it is 
dependent on the clinical context, patient characteristics (mainly oncological patients or subjects with 
known endocrine diseases have been included), and the technology used. The data obtained by first-
generation CT scans showed a very low prevalence of about 0.6% (26). In the following decade, the 
introduction of more advanced CT scans resulted in an increased frequency of about 4%, but different 
criteria were used and either oncological patients or subjects with a known diagnosis of 
hypercortisolism were included (7,23,24). More recent studies have shown that adrenal masses can be 
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found in up to 10% of patients with lung cancer (27). Interestingly, a large study involving all 
hospitals in Western Sweden reported that the frequency increased from only 0.9% at the first 
radiological evaluation to 4.5% after a central radiologic revision (23). This suggests the possibility of 
an underestimation when the evaluation is not carried out by experienced radiologists. The difference 
was striking, particularly when thoracic CT (extended to the upper abdomen) was considered (23). 
We found a frequency of bilateral adrenal adenomas of 29.5%, a figure that is higher than previously 
reported. In the literature, the frequency of bilateral adrenal masses (not only adenomas) ranged from 
0% to 25.1% (2,7,8,23-25,28,29). Our study highlights also the importance of a dedicated re-
assessment of CT images of any adrenal mass found with a standard radiologic protocol. Interestingly, 
a previous study employing central revision of CT images reported a frequency of bilateral masses 
alike the present one (25.1%) (23). In our study, a thickness and reconstruction interval of 1 mm of 
the whole tumoral area allowed for a more precise assessment of mass density, showing that 25.6% of 
adrenal adenomas present with unenhanced density between 10 HU and 24 HU (Figure 1). Previous 
studies reported variable estimates, ranging from 12% to 55% (8,29). 
The strength of our study is that the patients were assessed prospectively in a single center, only those 
referred for abdominal CT were selected, and patients with known or suspected cancer were excluded. 
The improved methodology in our study (i.e., the revision of all scans by experienced radiologists) 
could explain the higher frequency than reported in previous studies, with a figure that is close to that 
of autopsy series. The highest prevalence reported in autopsy series is about 9%, although significant 
discrepancies of the reported data can occur, depending on the ability to distinguish between 
hyperplasia and small nodules (26).  
The age pattern in our series is similar to those found in previous studies, but the sex distribution 
differs. We have observed a male predominance, while the bulk of evidence suggests a higher 
frequency of adrenal incidentalomas in women (5,23). The only findings in agreement with ours are 
from the recent COAR study (28), which reports a male to female ratio of 1.35. Our assumption is that 
the specific sex distribution in our study reflects the characteristics of the overall population from 
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which the series was derived, as a similar sex ratio was found in the population undergoing CT 
examinations at the Radiology Department where the study was conducted.  
A major finding of our study is that adrenal incidentalomas are associated with a higher risk of type 2 
diabetes. The patients bearing adrenal incidentalomas have higher BMIs and larger waists, which is 
consistent with a higher frequency of diabetes. Since the prevalence of either type 2 diabetes or 
adrenal incidentalomas increases with age, it may be speculated that their association is an effect of 
aging. However, the correlation between the frequency of adrenal incidentalomas, diabetes and age 
was not fully linear. Moreover, patients with adrenal incidentalomas were not older than patients 
without, and age did not differ between patients bearing adrenal incidentalomas with or without 
diabetes.  
The novelty of our findings is that our cohort was unselected; thus, to the best of our knowledge, this 
is the first unbiased demonstration of a link between adrenal incidentalomas and type 2 diabetes. 
Discovering adrenal masses in diabetic patients is more likely because they are more extensively 
studied and followed due to their disease and accompanying comorbidities (20), but this potential 
limitation does not apply to our study. Our study cohort, from which patients with adrenal 
incidentalomas were drawn, was composed of outpatients who showed a prevalence of diabetes 
comparable with the background population of our region (21).  
The present data provide strong evidence to support the view that patients with adrenal 
incidentalomas have a worse metabolic profile, which is associated with increased cardiovascular risk 
(13-16,18). The observation that diabetes was an independent predictor of the presence of adrenal 
tumors points to the relationship with insulin resistance, which may be bidirectional, as recently 
argued by Sydney et al. (30). An adrenal adenoma may be a possible cause of insulin resistance and 
metabolic syndrome (14), but insulin resistance by itself may facilitate the occurrence of adrenal 
tumors (31,32).  
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It is well recognized that type 2 diabetes mellitus represents a risk factor for different cancer types 
(30), through pathways including the production of TNF-alpha by adipose tissue (33), 
hyperinsulinemia, and hyperglycemia (34,35). 
In terms of the assessment of cortisol secretion, we confirm that approximately half of the patients 
with adrenal incidentalomas have possible autonomous cortisol secretion, according to the definition 
in the ESE/ENSAT guidelines (10). Due to the small subgroups, we were not able to separately 
consider patients with definitive autonomous cortisol secretion, and we compared only two groups 
stratified by post-DST cortisol of 50 nmol/L, and found no difference in the comorbidity burden 
between them.  
The possibility that even non-functioning adrenal incidentalomas may predict an increased risk of 
diabetes has been proposed by Lopez et al. (36), who demonstrated in a longitudinal retrospective 
study how the frequency of incident diabetes found during the follow-up was higher for patients with 
non-secretory tumors than for those without. More recent studies have suggested that the lack of 
autonomous cortisol secretion does not exclude an adverse metabolic and cardiovascular profile 
(13,30,37). A recent meta-analysis assessing morbidity and mortality in patients with adrenal 
incidentalomas found that diabetes was twice as frequent in patients with autonomous cortisol excess 
than in patients with non-secretory tumors, although the latter still had a frequency of diabetes higher 
than the general population (38).  
To conclude, we have shown in a contemporary and prospective radiological series that the frequency 
of unsuspected adrenal tumors (adrenal incidentalomas) is higher than previously reported. In 
addition, the findings support the association between adrenal incidentalomas and type 2 diabetes. 
Although this has previously been identified (39), strength of the present study is that our findings are 
free from ascertainment bias, since patients with adrenal incidentalomas were drawn from a cohort of 
outpatients showing a risk of diabetes comparable with the background population of our region. The 
prospective recruitment of our series, and the fact that it was not enriched a priori by diabetic patients, 
provide strong support to the concept. We acknowledge the limitation that due to the small sample 
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size of adrenal tumors, the subgroup analysis was not able to establish whether autonomous cortisol 
secretion has a role in this association. However, the present study provides evidence for a better 
understanding of whether adrenal incidentalomas are associated with comorbid conditions. Given the 
frequency of adrenal incidentalomas, which in the present series was even higher than previously 
thought, the issue is of importance for public health. 
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TABLES 
Table 1. Baseline features of patients. 
 
N= 601 
Male sex  331 (55.1) 
Age, years   63.5 ±14.4 
BMI   25.4 ± 4.9 
Waist, cm  93.1 ± 13.9 
Menopausal status§   208 (77) 
Smoking  132 (22) 
Hypertension   335 (55.4) 
Type 2 Diabetes  93 (15.5) 
HbA1c*, % 7.5 ± 1.93 
Dyslipidemia 104 (17.3) 
History of CV events  102 (17) 
 
Data are expressed as mean ± SD or as absolute value and percentage as appropriate. 
§Menopausal status refers to women only. 
*HbA1c values refer to 90 diabetic patients. 
Abbreviations: BMI = body mass index, HbA1c= glycosylated hemoglobin, CV= cardiovascular. 
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 Table 2. Comparison between patients with adrenal incidentalomas and patients without.   
 
 Patients with 
Adrenal Incidentalomas 
(44) 
Patients without 
Adrenal Incidentalomas 
(557) 
p value  
Male sex  32 (72.7) 299 (53.7) 0.0221 
Age, years  65.6 ± 10.3 63.3 ± 14.7 0.4007 
BMI   27.6 ± 6.2 25.6 ± 4.8 0.009 
Waist, cm  101.2 ± 13.9 92.7 ± 13.9 0.007 
Hypertension   28 (63.6) 307 (55.1) 0.29 
Type 2 Diabetes  14 (31.8) 79 (14.2) 0.0038 
HbA1c*,%  7.8 ± 2.9 7.2 ± 2.6 0.1446 
Dyslipidemia 11 (25) 93 (16.7) 0.2322 
History of CV events  7 (16.3) 95 (17.1) 0.9892 
 
Data are expressed as mean ± SD or as absolute value and percentage as appropriate. 
*HbA1c values refer to 14 diabetic patients with adrenal incidentalomas and 76 diabetic patients without adrenal 
incidentalomas. 
Abbreviations: BMI = body mass index, HbA1c= glycosylated hemoglobin, CV= cardiovascular. 
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Table 3. Multivariariate regression analysis of the features associated with the presence of an 
adrenal incidentaloma. 
 
N= 44 
 Beta value P value 
Male sex 0.053 0.216 
Smoking  0.082 0.057 
BMI 0.016 0.720 
Type 2 Diabetes  0.131 0.003 
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Table 4: Comparison between patients with cortisol levels after 1 mg dexamethasone 
suppression < 50 or ≥ 50 nmol/L.   
 
 Patients with cortisol 
levels after 1 mg 
dexamethasone 
suppression 
< 50 nmol/L. 
(20) 
Patients with cortisol 
levels after 1 mg 
dexamethasone 
suppression  
≥ 50 nmol/L 
(20) 
p  
Male sex (n,%) 16 (80) 
 
14 (70) 
 
0.465 
Age, years (mean ± SD) 62.6 ± 8.2 67.5 ± 9.5 0.429 
BMI  (media ± SD) 26.9 ± 5.6 28.5 ± 6.9 0.750 
Hypertension  (n,%) 9 (45) 15 (75) 0.053 
Diabetes (n,%) 6 (30) 7 (35) 0.736 
HbA1c, % (mean ± SD)*  7.1 ± 1.8 8.9 ± 3.8 0.114 
Dyslipidemia (n,%) 3 (15) 6 (30) 0.256 
History of CV events 
(n,%) 
2 (10) 4 (20) 0.376 
Size of the dominant 
nodule (mm) 
19.8 ± 7.6 27.4 ± 12.9 0.012 
ACTH (pmol/L) 3.5 ± 1.5 2.9 ± 1.8 0.114 
DHEAS (mol/L)  1.9 ± 1.1  1.7 ± 1.0 0.739 
Data are expressed as mean ± SD or as absolute value and percentage as appropriate. 
*HbA1c values refer to diabetic patients only. 
Abbreviations: BMI = body mass index, HbA1c= glycosylated haemoglobin, CV= cardiovascular. 
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Table 5. Frequency of adrenal incidentalomas in CT scan series. 
Study Study 
period 
Patients 
(n) 
Age at 
diagnosis 
(years) 
Female 
Sex 
(%)  
Type of 
CT 
Frequency of 
adrenal 
incidentalomas  
(%) 
Mass 
size 
(mm) 
Bilateral  
mass 
(%) 
Glazer 
1982 
NA 2200 NA NA NA 0.6 NA NA 
Prinz 
1982 
1981 1423 41 – 73 44.4 Abdominal  0.6 10-40 0 
Abecassis 
1985 
1983-
1985 
1459 NA NA NA 1.3 NA NA 
Belldegrun 
1986 
1976-
1983 
12000 NA NA Abdominal  0.7 NA NA 
Herrera 
1991 
1985-
1989 
61054 62 60.2 NA 0.4 25 
(10-
110) 
NA 
Caplan 
1994 
NA 1779 NA NA NA 1.90  NA 
Song 
2008 
Jan 
2000 - 
Dec 
2003 
65231 64 
(19 – 
100) 
NA Abdominal 
and 
thoracic 
 
1.5 
 
20 
(4 -
82) 
 
7.8 
 
Hammarstetd 
2010 
Oct 
2002 - 
Apr 
2004 
34044 69 
(30 – 94) 
56.9 Abdominal 
and 
thoracic  
4.5 25.8 
(8– 
94) 
25.1 
Bovio 
2011 
Apr 
2001-
Dec 
2001 
520 58 
(50 – 79) 
26.1 Chest scan 
4.4 12-38 13.2 
Davenport 
2011 
Jan 
2006 -
Dec 
2007 
3099 68 
(45 – 92) 
46 Abdominal 
and 
thoracic 
0.98 abdomen 
 
0.81 thorax 
26 ± 
12 
 
2.7 
Grossman 
2016 
NA 673 50.93 ± 
11.1 
NA Abdominal 
CT 
4.2 NA 11 
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Ab
brevi
ations: NA = Not available. 
 
Present study Jan 
2017 - 
Jun 
2018 
601 65.6 ± 
10.3 
27.3 Abdominal 
CT 
 
7.3 21 
(10-
50) 
29.5 
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Legends to figures. 
 
Figure 1. Scatterplot of the density (HU) and size (mm) of adrenal adenomas. 
 
Figure 2. Distribution of patients with adrenal adenomas (white bars) and patients with adrenal 
adenomas and diabetes (black bars) by age decades. 
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Figure 1 
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Figure 2 
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